Videos

Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.

Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time-the marker which currently provides the most information-and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Tim Moynihan of the Mayo Clinic in Minnesota discusses topics from the session he chaired at ASCO, "Effective Time Management for the Busy Oncologist," including why EHRs may not actually save physicians time; how to manage your email load; and tips for avoiding burnout, which he cites as a danger in such a physically and emotionally taxing profession.

In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.

Dr. Gianni has been involved with new drug therapies in medical oncology for some time, and in this interview he discusses the changing use of breast cancer treatments, neoadjuvant regimens, and research and developments on HER2-positive breast cancer.

John Mendelsohn, president of the MD Anderson Cancer Center, discusses with ONCOLOGY the recent advances in using a “systems approach” in oncology and how he believes this will affect outcomes in the future.

In this video interview, Joseph Connors gives an overview of the results presented here at ASCO of the phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, and discusses the most intriguing work currently being done with novel agents used to treat relapsed or refractory Hodgkin lymphoma.

Dr. Brenner discusses the role of chemopreventives, biomarkers, and early detection for cancer prevention.

Dr. Leachman discusses the use of genetic testing for cancer patients.

Dr. Correa discusses her work on brain tumors and genetics, and their contribution to adverse side effects.

Dr. Loprinzi discusses the role of diet and exercise in cancer prevention.